References
Miller DH, Leary SM (2007) Primary-progressive multiple sclerosis. Lancet Neurol 6:903–912
Mahad DH, Trapp BD, Lassmann H (2015) Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol 14:183–193
Maggi P et al (2018) Central vein sign differentiates multiple sclerosis from central nervous system inflammatory vasculopathies. Ann Neurol 83:283–294
Montalban X, Hauser SL, Kappos L (2017) Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med 376:209–220
Dong X, Xiaoou Yu, Li H, Kang H (2020) Identification of marker genes and pathways in patients with primary biliary cholangitis. J Comput Biol 27(6):923–933
Lundmark F, Duvefelt K, Iacobaeus E et al (2007) Variation in interleukin 7 receptor α chain (IL7R) influences risk of multiple sclerosis. Nat Genet 39:1108–1113
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
This article does not contain any studies with human participants or animals performed by any of the authors.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Bistriceanu, C.E., Danciu, F.A. & Cuciureanu, D.I. Overlap autoimmune syndrome: primary progressive multiple sclerosis, primary biliary cirrhosis, Raynaud phenomena with digital necrosis. Acta Neurol Belg 123, 283–285 (2023). https://doi.org/10.1007/s13760-021-01833-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13760-021-01833-9